Beijing-based biotech company EdiGene Inc – that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions – has raised about $15 million in a pre-Series B financing round led by Lilly Asia Ventures (LAV) a venture capital firm from Shanghai, according to an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
